The Zhitong Finance App learned that on August 6, Baiosetu-B (02315,688796.SH) announced a preliminary increase in 2026 semi-annual results. According to preliminary estimates by the company's finance department, it is expected to achieve operating income of 936 million yuan to 946 million yuan (RMB, same below) in the half-year of 2026. Compared with the same period of the previous year, it will increase 315 million yuan to 325 million yuan, an increase of 50.80% to 52.41%; achieve net profit attributable to owners of the parent company of 236 million yuan to 246 million yuan. Compared with the same period last year, it will increase by 391.87% to 412.71% over the previous year; achieving net deduction of non-recurring profit and loss attributable to the owners of the parent company Profit was 192 million yuan to 202 million yuan. Compared with the same period last year, it will increase 164 million yuan to 174 million yuan, an increase of 574.02% to 609.04% over the same period last year.
As the biomedical industry enters a new stage of innovation leading industrial development, the company relies on forward-looking research and development, leading products and high-quality services, and a high-quality customer network covering the world's top pharmaceutical companies and leading biotech companies to fully unleash its competitive advantage and deeply embrace the business development opportunities brought about by the rise in industry prosperity. During the reporting period, the company's two major business lines achieved two-wheel drive and leapfrog collaboration, driving continuous rapid growth in revenue.
Relying on the significant increase in the company's revenue scale and position in the industry, the scale effect of the company's production capacity and operation is showing at an accelerated pace. On this basis, combined with the continuous deepening of superimposed lean management, the company effectively reduced costs and increased efficiency, driving a further increase in overall gross margin, effectively reducing the cost ratio during the period, significantly increasing the company's profitability, and accelerating the release of large-scale profits.
Baiosetu is an international biotechnology company that drives the development of new drugs through innovative technology, and is committed to becoming a global birthplace of new drugs. With self-developed gene editing technology as the core, the company has built a dual-engine platform of “whole-human antibody molecular bank+target humanized mouse bank” to systematically accelerate global drug research and development.
Baiosetu independently developed the renMICE® whole-human antibody platform (covering RenMAb®, RenLite®, renNano®, rentCR®, rentCR mimic®) for the discovery of therapeutic all-human monoclonal antibodies, bis/polyspecific antibodies, dual-antibody ADCs, nanoantibodies, and TCR-like antibodies. Focusing on 1000+ potential drug targets, the company is promoting a large-scale antibody discovery program — “Thousand Mouse Antibodies™”. It has built a library of more than 1 million real whole human antibody sequences, and opened up global cooperation.
As of December 31, 2025, Baiosetu has signed more than 350 drug cooperative development/licensing/transfer agreements. The company's sub-brand Baiao Animal has established thousands of gene-edited animal/cell models, has the world's leading target humanized mouse library, and provides global customers with full-chain capability support such as preclinical pharmacological efficacy research, gene editing services and model construction. Biosetu is headquartered in Beijing, and has branches in China (Haimen, Jiangsu, Shanghai), the United States (Boston, San Francisco, San Diego), and Heidelberg, Germany, to form a global R&D and operation network.